Scottsdale, AZNCT06450873Now EnrollingIRB Ready

Estrogen Receptor-Positive Breast Carcinoma Clinical Trial in Scottsdale, AZ

Access cutting-edge estrogen receptor-positive breast carcinoma treatment through this phase 2 clinical trial at a research site in Scottsdale. Study-provided care at no cost to qualified participants.

Sponsored by Mayo Clinic

Quick Self-Assessment

See if you qualify for this Scottsdale location

Preparing your pre-screening questions…

Expert Care in Scottsdale

Access estrogen receptor-positive breast carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related estrogen receptor-positive breast carcinoma treatment provided free

Apply for This Scottsdale Location

Check if you qualify for this estrogen receptor-positive breast carcinoma clinical trial in Scottsdale, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Scottsdale

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Scottsdale site if eligible
  4. 4Begin participation

About This Estrogen Receptor-Positive Breast Carcinoma Study in Scottsdale

This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom. In traditional Chinese medicine, it is used for enhancing function and removing toxins, as well as for cancer, hepatitis, and infections. There is previous evidence of significant tumor shrinkage occurring in the 2-month window between diagnosis and surgery in women who have taken TTM. Giving TTM may be effective in treating post-menopausal women with HER2-negative, ER-positive breast cancer undergoing surgery.

Sponsor: Mayo Clinic

Who Can Participate

Inclusion Criteria

Women ≥ 18 years of age
Histological confirmation of ER+, HER2- breast cancer, newly diagnosed and tissue available for central confirmation of Ki-67 measurement. Subjects are eligible if they have a Ki-67 of ≥10%. Ki-67 will be repeated for patients who have had this done externally.
Scheduled for definitive breast surgery
Detectable disease as defined by mammography, breast ultrasound of greater than 5mm in size.
NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible
Post menopausal as defined by:
Self-reported last menstrual period greater than 12 months, or
Bilateral oophorectomy, or
Follicle stimulating hormone (FSH) \>20 mIU/mL, and estradiol level ≤ 20 pg/mL
Not taking aromatase inhibitor or a selective estrogen receptor modifier
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 obtained ≤ 90 days prior to registration
Platelet count ≥ 100,000/mm\^3 (obtained ≤ 90 days prior to registration)
Absolute neutrophil count (ANC) ≥ 1,000/mm\^3 (obtained ≤ 90 days prior to registration)
Hemoglobin ≥ 11 g/dL (obtained ≤ 90 days prior to registration)
Serum transaminase \[alanine aminotransferase (ALT) or aspartate aminotransferase (AST)\] ≤ 1.2 x upper limit of normal (ULN) (obtained ≤ 90 days prior to registration)
Alkaline phosphatase ≤ 1.2 x ULN (obtained ≤ 90 days prior to registration)
Serum creatinine ≤ 1.2 x ULN (obtained ≤ 90 days prior to registration)
Provide written informed consent
Ability to complete the Symptom Experience Diary by themselves or with assistance

Exclusion Criteria

Ki-67 of \<10%
Current use of any medicinal mushrooms
Patient with locally advanced cancer who will require neoadjuvant therapy or metastatic cancer
Currently on systemic chemotherapy
Concurrent endocrine therapy (selective estrogen receptor modifiers or aromatase inhibitors)
Allergy to mushrooms
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
Immunocompromised patients
Patients known to be HIV positive and currently receiving antiretroviral therapy.
NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
Uncontrolled intercurrent illness including, but not limited to:
Ongoing or active infection
Symptomatic congestive heart failure
Unstable angina pectoris
Cardiac arrhythmia
Or psychiatric illness/social situations that would limit compliance with study requirements
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Other active malignancy 3 years prior to registration
EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix
NOTE: If there is a history of prior malignancy, they must not be receiving chemotherapy treatment for their cancer

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Scottsdale?

Yes, this clinical trial (NCT06450873) has an active research site in Scottsdale, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Estrogen Receptor-Positive Breast Carcinoma Treatment Options in Scottsdale, AZ

If you're searching for estrogen receptor-positive breast carcinoma treatment options in Scottsdale, AZ, this clinical trial (NCT06450873) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Scottsdale research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced estrogen receptor-positive breast carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all estrogen receptor-positive breast carcinoma clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Scottsdale, AZ

See all breast cancer clinical trials recruiting in Scottsdale — not just this study.

Browse Breast Cancer Trials in Scottsdale →

Browse More Trials by Condition

Breast Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Scottsdale?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Scottsdale, AZ